The investigational BTK inhibitor tolebrutinib did not lower the risk of confirmed disability progression compared with placebo in people with primary progressive multiple sclerosis (PPMS), failing to meet the main goal and several key secondary goals of the Phase 3 PERSEUS trial. It did, however, show signs of benefit on MRI scans, including fewer new […]
The post ACTRIMS 2026: Tolebrutinib misses main goal in PPMS Phase 3 PERSEUS trial appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com